Antengene Unveils Breakthrough Clinical Findings
Antengene Corporation Limited is a pioneering global biopharmaceutical company dedicated to bringing innovative therapies to the market for patients facing hematologic malignancies and solid tumors. Their mission aligns with the vision of improving patient care across borders, making critical advancements in the field of oncology.
Recently, Antengene announced the much-anticipated presentation of significant clinical findings at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. This prestigious event is set to take place from May 30 to June 3, where Antengene will showcase the efficacy and innovative potential of its leading candidates, the CD73 inhibitor ATG-037 and the mTORC1/2 inhibitor ATG-008, through Poster Presentations.
Latest Developments with CD73 Inhibitor ATG-037
ATG-037 has emerged as a key focal point in Antengene's research. It stands as a small molecule inhibitor targeting CD73, which plays a crucial role in tumor immune evasion. The results of the STAMINA-01 trial, designed to evaluate ATG-037 both as a monotherapy and in combination with pembrolizumab, have generated notable interest due to their promising preliminary results in melanoma and non-small cell lung cancer (NSCLC).
During the ASCO meeting, detailed insights will be shared regarding the Phase I/Ib trial's progression and the current dose optimization efforts underway in selected countries. The hope is to demonstrate how ATG-037 can be an effective option for patients who have exhausted other treatment avenues.
Study Details of ATG-037
The poster presentation for ATG-037 will include the following details:
Title: A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01
Abstract: 3123
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date: June 2
Time: From 1:30 PM to 4:30 PM (Central Time)
Introducing mTORC1/2 Inhibitor ATG-008
In addition, Antengene will present findings from the ATG-008, a small molecule mTORC1/2 inhibitor, which has shown strong therapeutic potential when combined with toripalimab for patients with advanced cervical cancers. This therapy aims to address the needs of patients who have not benefitted from prior anti-PD-1 treatments.
The information shared at the ASCO meeting will offer insights into the potential of mTORC1/2 inhibitors in enhancing treatment efficacy for specific cancers, thereby paving the way for new combinations in cancer therapy.
Study Details of ATG-008
The details for the ATG-008 poster presentation will encompass:
Title: A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy
Abstract: 5540
Session: Gynecologic Cancer
Date: June 1
Time: From 9:00 AM to 12:00 PM (Central Time)
The Vision Behind Antengene
Antengene has crafted a diverse pipeline that showcases its commitment to innovation in oncology. With a blend of proprietary therapies in various development phases, the company aims to address the comprehensive needs of cancer patients globally.
At present, Antengene has made substantial progress, having secured 31 investigational new drug (IND) approvals across different markets, alongside the submission of new drug applications (NDAs) in multiple Asia Pacific countries. Notably, their NDA for XPOVIO (selinexor) has received approval in several regions, marking significant strides for the company and the patients they serve.
Frequently Asked Questions
What are the key drugs being presented by Antengene at ASCO 2025?
Antengene will present clinical data on the CD73 small molecule inhibitor ATG-037 and mTORC1/2 small molecule inhibitor ATG-008.
What is the significance of the STAMINA-01 trial?
The STAMINA-01 trial evaluates the efficacy of ATG-037 in treating advanced solid tumors in combination with KEYTRUDA and aims to provide promising results in resisting treatments.
When and where will the ASCO meeting take place?
The ASCO Annual Meeting will be held from May 30 to June 3 in Chicago, showcasing important advancements in oncology.
What is Antengene's approach towards cancer treatment?
Antengene focuses on innovative, first-in-class treatments to overcome limitations in current oncological therapies and improve patient outcomes on a global scale.
How is Antengene advancing its drug development pipeline?
By securing IND approvals and submitting NDAs in various markets, Antengene is enhancing its capacity to bring new therapies to market effectively.
